AbbVie will begin the initiative Feb. 1, according to a Dec. 29 letter the drugmaker sent to safety net hospitals.
This move makes AbbVie the 11th drugmaker to restrict 340B discounts. It joins Amgen, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Merck, Novartis, Novo Nordisk, Sanofi, UCB and United Therapeutics.
On Dec. 20, more than 800 hospitals participating in the 340B drug-pricing discount program penned a letter to HHS, asking the federal government to appeal a Nov. 5 federal court decision that upheld price denials from two drugmakers. The hospitals said drugmakers have been unilaterally denying 340B pricing to hospitals partnering with contract pharmacies to dispense drugs.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
